Revive Therapeutics Ltd.
Revive Therapeutics Ltd.
Your view on RVV.CN
Overview
What the company does, where it operates, and who runs it.
About Revive Therapeutics Ltd.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Michael Frank
- Headquarters
- CA
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Michael Frank
- Headquarters
- CA
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases.
It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch.
The company was incorporated in 2012 and is headquartered in Toronto, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Revive Therapeutics Ltd., and the rating behind it. RVV.CN last traded at C$0.01; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Revive Therapeutics Ltd.. Starting points for Revive Therapeutics Ltd.: EPS -C$0.02, beta 0.28 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Revive Therapeutics Ltd.. Revive Therapeutics Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Revive Therapeutics Ltd.. Trailing twelve-month EPS for Revive Therapeutics Ltd. stands at -C$0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Revive Therapeutics Ltd.. Revive Therapeutics Ltd. has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Revive Therapeutics Ltd. valued side by side against its closest peers. Revive Therapeutics Ltd. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Revive Therapeutics Ltd., and how their positions are changing. At a C$6.5M market value, institutional positions materially move Revive Therapeutics Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Revive Therapeutics Ltd. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Revive Therapeutics Ltd.. Revive Therapeutics Ltd. is a C$6.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Revive Therapeutics Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Revive Therapeutics Ltd.. Coverage tracks Revive Therapeutics Ltd. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.